Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-β treatment for chronic hepatitis C

Hepato-Gastroenterology

Volumn 51, Issue 58, 2004, Pages 1109-1114

  Ebinuma, Hirotoshi ^f   Saito, Hidetsugu ^a   Tada, Shinichirou ^a   Masuda, Tetsuya ^b   Kamiya, Tomoyoshi ^c   Nishida, Jiro ^d   Yoshioka, Masahiro ^e   Ishii, Hiromasa ^a  

^a KEIO UNIVERSITY   (Japan)

^b Sano Kousei General Hospital   (Japan)

^c Keiyu Hospital   (Japan)

^d TOKYO DENTAL COLLEGE   (Japan)

^e Minami tama Hospital   (Japan)

^f NONE

Author keywords

Chronic hepatitis C; In vitro immunoglobulin production; Interferon ; Liver extract preparation and flavin adenine dinucleotide mixture

Indexed keywords

ADERAVIN 9; FLAVINE ADENINE NUCLEOTIDE; IMMUNOGLOBULIN; LIVER EXTRACT; RECOMBINANT BETA INTERFERON;

ADULT; ANGINA PECTORIS; ARTICLE; CELL CULTURE; CHEMICAL ANALYSIS; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE EXACERBATION; DRUG POTENTIATION; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; HUMAN CELL; HYPOTHYROIDISM; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MONOTHERAPY; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; PSYCHIC EXCITEMENT; RASH; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUPERNATANT; THORAX PAIN; THROMBOCYTOPENIA;

ADULT; ANTIVIRAL AGENTS; DRUG SYNERGISM; FEMALE; FLAVIN-ADENINE DINUCLEOTIDE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULINS; INTERFERON-BETA; LIVER EXTRACTS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 3042660487     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka N, Arakawa Y, Omata M: Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997; 113:558-566.
2. Yoshioka K, Yano M, Kusakabe A, Hirofuji H, Fuji A, Kuriki J, Arao M, Murase K, Kidokoro R, Kakumu S: Randomized controlled trial of lymphoblastoid interferon-α for chronic hepatitis C (Comparison of 9-MU and 6-MU doses). IFN Treatment Group of Affiliated Hospitals of the Third Department of Internal Medicine at Nagoya University School of Medicine. Am J Gastroenterol 1999; 94:164-168.
3. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZB, Ling MH, Cort S, Albrecht JK: Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
4. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
5. Fuziwara K, Mochida S, Matsuo S, Ogata I, Hayashi S, Sato Y: Randomized control trial of interferon-β injections at 12-h intervals as a therapy for chronic hepatitis C. Hepatol Res 1998; 12:240-251.
6. Izumi N, Kumada H, Hashimoto N, Harada H, Imawari M, Zeniya M, Toda G: Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study. Dig Dis Sci 2001; 46:516-523.
7. Asahina Y, Izumi N, Uchihara M, Noguchi O, Tsuchiya K, Hamano K, Kanazawa N, Itakura J, Miyake S, Sakai T: A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology 2001; 34:377-384.
8. Yokochi S, Ishiwata Y, Saito H, Ebinuma H, Tsuchiya M, Ishii H: Stimulation of antiviral activities of interferon by a liver extract preparation. Arzneimittelforschung 1997; 47:968-974.
9. Saito H, Ebinuma H, Tada S, Tsunematsu S, Atsukawa K, Masuda T, Tsuchiya M, Ishii H: Enhancing effect of the liver extract and flavin adenin dinucleotide mixture on anti-viral efficacy of interferon in patients with chronic hepatitis C. Keio J Med 1996; 45:48-53.
10. Atsukawa K, Saito H, Ebinuma H, Morizane T, Takahashi M, Ohishi T, Kumagai N, Tsuchimoto K, Ishii H: Reduced in vitro immunogloburin secretion from peripheral blood mononuclear cells in responders to high-dose interferon-α2b treatment for chronic hepatitis C. Hepatogastroenterology 2000; 47:1685-1690.
11. Saito H, Ebinuma H, Takahashi M, Atsukawa K, Ohishi T, Ishii H, The Keio Interferon-β Study Group: Short-course of interferon-β for the treatment of chronic hepatitis C: a multicenter trial for evaluating host immunological parameters. Int J Immunotherapy 1998; 14:115-128.
12. Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, Kamimura T, Yamada G, Hino K, Yokosuka O, Suzuki H: New Inuyama classification; new criteria for historogical assessment of chronic hepatitis. Int Hepatol Com 1996; 6:112-119.
13. Ravaggi A, Biasin MR, Infantolino D, Cariani E: Comparison of competitive and non-competitive reverse transcription-polymerase chain reaction (RT-PCR) for the quantification of hepatitis C virus (HCV) RNA. J Virol Methods 1997; 65:123-129.
14. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi M: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73:673-679.
15. Enomoto N, Sakuma N, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Eng J Med 1996; 334:77-81.
16. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Diensatg JL, VanThiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A and the Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon a. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321:1501-1506.
17. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon α therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321:1506-1510.
18. Saito H, Ebinuma H, Oda M, Ishii H, Keio Natural IFN-α Study Group: Results of the multicenter natural interferon-α treatment for chronic hepatitis C: Correlation between total dose, administration periods and efficacy of therapy. Keio J Med 1997; 46:177-183.
19. Saito H, Tsuchimoto K, Miyaguchi S, Tada S, Sawaguchi K, Komatsu H, Kaneko K, Watanabe T, Morizane T, Ishii H: Keio multicenter trial in high-dose interferon α-2b treatment for chronic hepatitis C. Keio J Med 1996; 45:161-167.
20. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K: Factors predictive of response to interferen-α therapy in hepatitis C virus infection. Hepatology 1994; 19:1088-1094.
21. Martinot-Peignoux M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V, Auperin A, Degott C, Benhamou JP, Erlinger S, Marcellin P: Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998; 29:214-223.
22. Perez R, Pravia R, Artimez ML, Giganto F, Rodriguez M, Lombrana JL, Rodrigo L: Clinical efficacy of intramuscular human interferon-β vs interferon α-2b for treatment of chronic hepatitis C. J Viral Hep 1995; 2:103-106.
23. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, Tozuka S, Izumi N, Marumo F, Sato C: Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997; 25:750-753.
24. Fukutomi T, Fukutomi M, Iwao M, Watanabe H, Tanabe Y, Hiroshige K, Kinukawa N, Nakamuta M, Nawata H: Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C. Med Sci Monit 2000; 6:692-698.
25. Shiratori Y, Nakata R, Shimizu N, Katada H, Hisamitsu S, Yasuda E, Matusmura M, Narita T, Kawada K, Omata M; IFN-β Research Group: High viral eradication with a daily 12-week natural interferon-β treatment regimen in chronic hepatitis C patients with low viral load. Dig Dis Sci 2000; 45:2414-2421.
26. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T: Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999; 116:378-386.
27. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131:174-181.
28. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M: Histologic improvement of fibrosis in patients with chronic hepatitis C who have sustained response to Interferon therapy. Ann Intern Med 2000; 132:517-524.
29. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koide I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H: The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79:1494-1500.
30. Iino S, Tango T, Matsushima T, Toda G, Miyake K, Hino K, Kumada H, Yasuda K, Kuroki T, Hirayama C, Suzuki H: Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol Res 2001; 19:31-40.
31. Takano S, Ito Y, Yokosuka O, Ohio M, Uchiumi K, Hirota K, Omata M: A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20:558-564.
32. Lirussi F, Beccarello A, Bortolato L, Morselli-Labate AM, Crovatto M, Ceselli S, Santini G, Crepaldi G: Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver 1999; 19:381-388.
33. Oka H, Yamamoto A, Kuroki T, Harihara S, Marumo T, Kim S-R, Monna T: Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995; 76:743-749.
34. Kiso S, Kawata S, Tamura S, Imai Y, Inui Y, Nagase T, Maeda Y, Yamasaki E, Tsushima H, Igura T, Himeno S, Seki K, Matsuzawa Y: Efficacy of combination therapy of interferon-alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled trial. J Gastroenterol 1997; 32:56-62.
35. Abdelmalek MF, Harrison ME, Gross JB Jr., Poterucha JJ, Gossard AA, Spivey JR, Rakela J, Lindor KD: Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial. J Clin Gastroenterol 1998; 26:130-134.
36. Kakumu S, Aoi T, Funayama A: Effect of liver extraction on the reaction of lymphocytes in patients with chronic liver diseases. Kan Tan Sui 1984; 8:739-742. (In Japanese)
37. Ikeda K, Satoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correlation with proportional hazard analysis. Hepatology 1999; 29:1124-1130.
38. Löhr HF, Fleischer B, Michel G, Rossol S, Hess G, Meyer zum Bushenfelde KH, Manns M: Hepatitis C virus antibody secretion by peripheral blood lymphocytes. J Hepatol 1992: 14:112-117.
39. Löhr HF, Nagel C, Dienes HP, Simpson B, Michel G, Georgen B, Meyer zum Bushenfelde KH, Gerken G: Significance of IgG and IgM HCV antibody secretion in vitro in patients with chronic hepatitis C: correlation with disease activity and response to interferon-α. Hepatology 1994; 20:1383-1389.